RE:One Year Old Interview But Very Enlightening PA: Many of our readers are interested in gaining exposure to this nascent space via investments. What would you say to those looking to invest in this emerging sector?
RM: My advice to people who are thinking about investing in this space is that they should pay close attention to organizations that currently have a clinical infrastructure in which they see patients, a positive cash flow, that are operating a profitable business, have a scale and growth, have a track record of doing their own clinical research, and have commercialization opportunity with their own products. There is no other organization in ketamine or psychedelic research that has the clinical infrastructure, the human capital, and their own IP commercialization products like we do. Moreover, we have the largest research footprint in the world and are able to produce products that are in early phase 2. We have joined with our extensive pharmaceutical partners to bring products across the finish line in about two years rather than the conventional 6 to 8 years.
I like this part from the interview